Clinical pharmacology provides a valuable opportunity to accelerate the near-term development of existing repurposed drugs for COVID-19 treatment and therapy.
PRINCETON, N.J.—May 21, 2020 — New executives bring strategic and cross-disciplinary expertise to navigate changing regulatory environments
A quantitative modeling approach can be used to predict the optimal time to administer influenza vaccine during pregnancy to provide protection to infants at birth.
Watch this webinar to learn about tools & processes to help tailor COVID-19 therapies for special populations, including children and pregnant women
Innovative contracts are helpful in navigating an evolving pharma marketplace while providing new approaches to distributing life-saving treatments to patients.
Certara applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19
This blog discusses how decision analysis approaches can help drug developers to better decisions under multiple criteria and uncertainty.
Certara Launches New Version of Simcyp® Simulator for Population-Based Pharmacokinetic Modeling and Simulation
Version 19 offers mechanistic models for assessing maternal-fetal drug risk, developing drug formulations, and optimizing dermal and transdermal drug development
COVID-19: Building for Today and Tomorrow – Therapeutic Considerations for Children and Pregnant Women
There are unique considerations to factor in treating COVID-19 in children and pregnant women. While COVID-19 disease among children have been less severe than in adults, very young children appear to be at the highest risk of severe disease. Join this webinar to learn how we can build tools and processes to help tailor therapies […]